Abstract:Objective: To assess the efficacy and tolerability of quetiapine in Chinese patients hospitalized with acute bipolar mania.Methods: This was a 4-week, multicenter, randomized, double-blind, lithium-controlled, parallel-group study. Secondary endpoints in the primary analysis were: response rate (>= 50% decrease from baseline in YMRS total score) and remission rate as defined using 3 criteria: YMRS total score <= 12, YMRS total score <= 12 + MADRS total score <= 8, and YMRS total score <= 8. Other measures included: change from baseline at Day 28 in YMRS, PANSS, and MADRS total score. Adverse event (AE) data were collected throughout the study.Results: 73 (94.8%) quetiapine and 62 (80.5%) lithium patients completed the study. Mean (SD) quetiapine doses for the ITT population and responders were 648.2 (111.84) mg/day and 637.5 (118.78) mg/day, respectively, while mean lithium concentrations for the ITT population and responders were 0.80 (0.28) mmol/L and 0.80 (0.22) mmol/L, respectively. Of patients who responded to quetiapine at Day 28, 88.3% were receiving 600-800 mg/day. At Day 28 YMRS response rate was significantly greater with quetiapine than lithium (77.9% vs. 59.7%, p = 0.0132), and remission rates using the 3 criteria were significantly greater with quetiapine than lithium: YMRS total score <= 12 (70.1% vs. 48.1%, p = 0.0071), YMRS <= 12 + MADRS <= 8 (70.1% vs. 48.1%; p = 0.0071), and YMRS <= 8 (51.9% vs. 32.5%; p = 0.0147). Significant decreases were observed in PANSS, YMRS, and MADRS total scores for both groups. The most common AEs experienced by patients receiving quetiapine were constipation, dizziness, diarrhea, alanine aminotransferase increase, palpitations, aspartate aminotransferase increase, pharyngolaryngeal pain, upper respiratory tract infection and dry mouth. In patients receiving lithium, the most common AEs were nausea (16.9%), constipation (13.0%), vomiting (13.0%), nasopharyngitis (11.7%), dizziness (6.5%), diarrhea (6.5%), and upper respiratory tract infection (6.5%).Conclusion: Quetiapine was shown to be clinically effective in patients with acute bipolar mania. There were side effects with quetiapine similar to those reported in other studies that included other ethnic populations of patients.

Lurasidone Versus Quetiapine for Cognitive Impairments in Young Patients with Bipolar Depression: A Randomized, Controlled Study

Olanzapine Versus Lithium in the Acute Treatment of Bipolar Mania: A Double-Blind, Randomized, Controlled Trial

Efficacy and Safety of Quetiapine Extended Release Monotherapy in Bipolar Depression: a Multi-Center, Randomized, Double-Blind, Placebo-Controlled Trial

Efficacy of Quetiapine Monotherapy and Combination Therapy for Patients with Bipolar Depression with Mixed Features: A Randomized Controlled Pilot Study

The Impact of Quetiapine Monotherapy or in Combination with Lithium on the Thyroid Function in Patients with Bipolar Depression: A Retrospective Study

Gut Microbiota in Bipolar Depression and Its Relationship to Brain Function: an Advanced Exploration

Efficacy and Safety of Lurasidone vs. Quetiapine XR in Acutely Psychotic Patients With Schizophrenia in Korea: A Randomized, Double-Blind, Active-Controlled Trial

Response and Remission Rates in Chinese Patients with Bipolar Mania Treated for 4 Weeks with Either Quetiapine or Lithium: a Randomized and Double-Blind Study.

Discontinuation Rate of Lurasidone and Quetiapine Extended Release in Bipolar Depression

Efficacy of Repetitive Transcranial Magnetic Stimulation with Quetiapine in Treating Bipolar II Depression: a Randomized, Double-Blinded, Control Study

Efficacy and safety of lurasidone versus placebo as adjunctive to mood stabilizers in bipolar I depression: A meta-analysis

Randomized controlled 16-week trial of the effect of quetiapine on the quality of life and cognitive functioning of patients in acute episodes of schizophrenia

Effects of short-term quetiapine and lithium therapy for acute manic or mixed episodes on the limbic system and emotion regulation circuitry in youth with bipolar disorder

Efficacy and Safety of Adding Lurasidone to Ongoing Therapy With Lithium or Valproate for the Treatment of an Acute Bipolar Depressive Episode

Efficacy and Safety of Quetiapine in the Treatment of Bipolar Acute Mania: a Randomized, Double-Blind, Lithium-Controlled Multicenter Study

Exploring Curative Effect of Quetiapine Fumarate in the Treatment of Bipolar Affective Disorder

Relationship between serum concentration and clinical response of quetiapine in adolescents and adults with bipolar disorders in acute stage: a prospective observational study

Efficacy and acceptability of lurasidone for bipolar depression: a systematic review and dose-response meta-analysis

Sleep Disturbance, Irritability, and Response to Lurasidone Treatment in Children and Adolescents with Bipolar Depression

Efficacy and Safety of Quetiapine-Xr As Monotherapy or Adjunctive Therapy to a Mood Stabilizer in Acute Bipolar Depression with Generalized Anxiety Disorder and Other Comorbidities: a Randomized, Placebo-Controlled Trial.

Pretreatment Alterations and Acute Medication Treatment Effects on Brain Task-Related Functional Connectivity in Youth with Bipolar Disorder: A Neuroimaging Randomized Clinical Trial.